Saturday 17 October 2026
Export FDMT’s income statement to Excel — free account
4D Molecular Therapeutics, Inc.
FDMT Healthcare Biotechnology
4D Molecular Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.2 million, up 230,194.6% from fiscal 2024. In the quarter to June 2026, revenue grew 25,106.7%, EPS fell 6.12% and free cash flow fell 61.3%, each against the same quarter a year earlier.
12.14
0.73
−5.67%
Follow FDMT
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | 4 | 3 | 2 | 5 | 2 | 4 |
P/S ratio |
12.67 | 12.67 | 12.67 | 19.58 | 33.73 | 213.40 | 40.13 | 8,120.76 | 5.10 |
Altman Z-Score |
— | — | — | 4.85 | 10.00 | 12.01 | 13.07 | 1.95 | 2.50 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 7.04 | (6.41) | 11.62 | 10.93 | 6.35 | 9.22 | 9.92 | 6.96 |
P/Operating CF |
(15.74) | (15.74) | (15.74) | (15.23) | (27.86) | (30.06) | (33.73) | (6.55) | 15.22 |
Beneish M-Score |
— | — | — | (1.99) | 41.91 | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 1.04 | 1.91 | 2.89 | 2.70 | 0.59 | 0.86 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 1.04 | 1.91 | 2.89 | 2.70 | 0.59 | 0.86 |
EV/Sales |
9.68 | 9.68 | 9.68 | (0.75) | 20.84 | 149.45 | 26.80 | (3,037.24) | 0.51 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 | 0.59 | 0.00 |
EV/Operating CF |
(2.29) | (2.29) | (2.29) | 0.20 | (5.44) | (5.39) | (7.33) | 0.84 | (0.40) |
EV/FCF |
(2.18) | (2.18) | (2.18) | 0.20 | (4.80) | (4.76) | (7.07) | 0.81 | (0.40) |
Quick Ratio |
4.09 | 11.53 | 3.91 | 16.62 | 15.17 | 13.58 | 15.21 | 14.58 | 9.15 |
Current Ratio |
4.15 | 11.68 | 4.05 | 16.88 | 15.69 | 14.02 | 15.65 | 14.92 | 9.39 |
Net Debt/EBITDA |
2.24 | 9.46 | 1.00 | 5.01 | 3.59 | 2.00 | 2.62 | 2.23 | 2.52 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.09 | 0.29 | 0.09 | 0.08 | 0.06 | 0.01 | 0.07 | 0.00 | 0.15 |
Operating CF/Net income |
(0.73) | 1.70 | 0.74 | 0.90 | 0.97 | 0.81 | 0.75 | 0.84 | 0.78 |
Capex/Depreciation |
0.00 | 0.00 | (3.19) | (0.69) | (4.06) | (3.33) | (0.94) | 1.50 | 13.40 |
Interest Coverage |
(253.30) | (24.47) | — | — | — | — | — | — | — |
| 47.58% | 40.49% | 98.07% | (61.82%) | (24.78%) | (39.06%) | (37.40%) | (39.31%) | (27.57%) | |
| (18.06%) | (19.70%) | (63.54%) | (32.72%) | (22.22%) | (34.94%) | (33.52%) | (35.74%) | (24.86%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (62.50%) | (386.72%) | (359.96%) | (136.94%) | (96.80%) |
Return on Tangible Assets |
(52.67%) | (10.79%) | (110.55%) | (20.92%) | (28.04%) | (47.35%) | (33.86%) | (37.82%) | (36.49%) |
Average Days of Receivables |
20.24 | 29.03 | 51.10 | 39.85 | 0.95 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
234.42% | 129.95% | 554.22% | 389.64% | 340.17% | 2,564.81% | 468.54% | 381,889.19% | 229.67% |
Selling, General and Administrative Expense of Revenue |
49.45% | 38.71% | 198.90% | 126.64% | 155.29% | 1,051.71% | 176.10% | 125,889.19% | 57.58% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 50.69% | 36.61% | 76.50% | 547.17% | 94.89% | 70,583.78% | 25.84% |
Graham Net Nets |
0.25 | 0.25 | 0.25 | 0.94 | 0.36 | 0.28 | 0.32 | 1.28 | 0.81 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(18.71%) | (18.71%) | (18.71%) | (21.27%) | (11.67%) | (16.09%) | (12.52%) | (53.50%) | (32.27%) |
Free Cash Flow Yield |
(35.06%) | (35.06%) | (35.06%) | (19.47%) | (12.86%) | (14.71%) | (9.45%) | (46.05%) | (25.23%) |
Revenue per Share |
0.23 | 0.57 | 1.36 | 2.12 | 0.65 | 0.10 | 0.53 | 0.00 | 1.47 |
Operating CF per Share |
0.33 | (0.65) | (7.14) | (7.92) | (2.49) | (2.68) | (1.94) | (2.49) | (1.88) |
Capex per Share |
0.00 | 0.00 | (0.62) | (0.16) | (0.33) | (0.36) | (0.07) | (0.07) | (0.01) |
Free Cash Flow per Share |
0.33 | (0.65) | (7.76) | (8.07) | (2.82) | (3.04) | (2.01) | (2.57) | (1.89) |
Cash per Share |
0.96 | 3.69 | 9.65 | 43.03 | 8.94 | 6.60 | 7.37 | 7.88 | 6.95 |
Shareholders Equity per Share |
(0.04) | 3.03 | (14.19) | 39.87 | 11.51 | 7.15 | 7.87 | 9.47 | 8.73 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.04) | 3.03 | (14.19) | 39.87 | 11.51 | 7.15 | 7.87 | 9.47 | 8.73 |
Free Cash Flow |
8.24 | (16.25) | (39.91) | (51.91) | (78.24) | (98.22) | (78.56) | (138.37) | (109.62) |
Working Capital |
18.59 | 86.01 | 39.55 | 265.91 | 239.94 | 204.78 | 277.64 | 405.78 | 369.15 |
Capital Expenditures |
(0.57) | (0.41) | (3.20) | (1.00) | (9.11) | (11.54) | (2.77) | (3.79) | (0.54) |
Net Current Asset Value |
(3.90) | 72.49 | (78.70) | 250.71 | 221.90 | 190.00 | 264.53 | 385.15 | 352.09 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 | 0.60 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.46 | 0.07 | 0.51 | 3.69 | 0.13 | 102.32 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.23 | 0.28 | 0.20 | 0.28 | 0.16 | 0.16 | 0.15 | (0.13) | 0.00 |
Cash ROIC |
36.18% | (9.72%) | 171.17% | (9.74%) | (13.80%) | (22.08%) | (13.18%) | (14.79%) | (12.07%) |
Accounts Receivable Turnover |
8.01 | 19.56 | 6.65 | 11.05 | 23.53 | 8.38 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.72 | 0.72 | 1.05 | 1.23 | 0.77 | 0.37 | — | — | — |
Average Payables |
0.71 | 0.71 | 1.35 | 1.77 | 3.28 | 4.04 | 3.42 | 3.95 | 7.77 |
Average Assets |
62.14 | 48.48 | 77.60 | 173.28 | 320.91 | 307.67 | 300.87 | 450.14 | 563.55 |
Average Common Equity |
(23.59) | (23.59) | (50.28) | 91.71 | 287.75 | 275.22 | 269.58 | 409.22 | 508.13 |
Columns are period end dates